PharmaCielo Ltd. (TSXV:PCLO)
Canada
· Delayed Price · Currency is CAD 0.0750
+0.0100 (15.38%)
Apr 1, 2025, 12:08 PM EST
PharmaCielo Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 3.48 | 1.54 | 5.31 | 1.94 | 2.65 | Upgrade
|
| Revenue Growth (YoY) | 125.70% | -70.96% | 172.93% | -26.71% | 237.26% | Upgrade
|
| Cost of Revenue | 2.75 | 2.91 | 4.27 | 6.12 | 8.65 | Upgrade
|
| Gross Profit | 0.73 | -1.37 | 1.04 | -4.17 | -5.99 | Upgrade
|
| Selling, General & Admin | 5.42 | 8.31 | 11.66 | 19.15 | 31.7 | Upgrade
|
| Other Operating Expenses | -0.24 | - | - | - | - | Upgrade
|
| Operating Expenses | 5.4 | 8.67 | 12.12 | 20.89 | 35.86 | Upgrade
|
| Operating Income | -4.67 | -10.04 | -11.08 | -25.06 | -41.85 | Upgrade
|
| Interest Expense | -2.26 | - | - | -0.2 | - | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0.07 | Upgrade
|
| Earnings From Equity Investments | - | - | -1 | -0.47 | -0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | 0.09 | -0.12 | -0.11 | 0.47 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.35 | -2.32 | -0.96 | -0.36 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -8.37 | -12.27 | -13.15 | -26.2 | -41.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.03 | -0.14 | -0.43 | -0.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.04 | - | - | Upgrade
|
| Asset Writedown | -0.82 | -4.23 | -1.27 | - | -1.25 | Upgrade
|
| Other Unusual Items | 0.05 | 0.18 | - | - | -0.89 | Upgrade
|
| Pretax Income | -9.14 | -16.3 | -14.52 | -26.63 | -43.76 | Upgrade
|
| Net Income | -9.14 | -16.3 | -14.52 | -26.63 | -43.76 | Upgrade
|
| Net Income to Common | -9.14 | -16.3 | -14.52 | -26.63 | -43.76 | Upgrade
|
| Shares Outstanding (Basic) | 171 | 160 | 151 | 146 | 113 | Upgrade
|
| Shares Outstanding (Diluted) | 171 | 160 | 151 | 146 | 113 | Upgrade
|
| Shares Change (YoY) | 6.83% | 6.03% | 3.67% | 29.41% | 17.17% | Upgrade
|
| EPS (Basic) | -0.05 | -0.10 | -0.10 | -0.18 | -0.39 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.10 | -0.10 | -0.18 | -0.39 | Upgrade
|
| Free Cash Flow | -1.97 | -5.17 | -10.4 | -21.21 | -28 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.03 | -0.07 | -0.15 | -0.25 | Upgrade
|
| Gross Margin | 21.00% | -88.78% | 19.55% | -214.48% | -225.77% | Upgrade
|
| Operating Margin | -134.06% | -651.38% | -208.69% | -1288.29% | -1577.02% | Upgrade
|
| Profit Margin | -262.70% | -1057.09% | -273.45% | -1369.14% | -1648.73% | Upgrade
|
| Free Cash Flow Margin | -56.59% | -335.01% | -195.86% | -1090.55% | -1054.97% | Upgrade
|
| EBITDA | -4.53 | -9.7 | -10.7 | -24.8 | -40.81 | Upgrade
|
| EBITDA Margin | -130.12% | - | -201.60% | - | - | Upgrade
|
| D&A For EBITDA | 0.14 | 0.34 | 0.38 | 0.26 | 1.04 | Upgrade
|
| EBIT | -4.67 | -10.04 | -11.08 | -25.06 | -41.85 | Upgrade
|
| EBIT Margin | -134.06% | - | -208.69% | - | - | Upgrade
|
| Revenue as Reported | 3.48 | 1.54 | 5.31 | 1.94 | 2.65 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.